Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

"Induction:~ASCT：20mg/56mg/m2 ,D1,8,15，C2-4; non ASCT: 20mg/36mg/m2 ,D1,8,15，C2-4;~Consolidation:~ASCT: 56mg/m2 ,D1,8,15，C5-6; non ASCT: 36mg/m2 ,D1,8,15，C5-8;~Maintenance:~ASCT: 70mg/m2 ，D1，15; non-ASCT：56mg/m2 ，D1，15 After consolidation therapy, if MRD negativity is sustained for more than 1 year, carfilzomib will be discontinued"

"28d/Cycle~Induction:~16mg/kg, D1,8,15,22，C 2-3，16mg/kg, D1,15, C4;~Consolidation:~ASCT: 16mg/kg/d, D1,15,C5-6; non ASCT: 16mg/kg/d, D1,15,C5-8;~Maintenance:~16mg/kg, D1,monthly After consolidation therapy, if MRD negativity is sustained for more than 1 year, daratumumab will be discontinued"

"28d/Cycle~Induction:~25mg qd d1-21 C2-C4;~Consolidation:~ASCT: 10mg d1-21，C5-6; non ASCT: 25 mg d1-21，C5-8;~Maintenance: 10mgqd D1-21~After consolidation therapy, if MRD negativity is sustained for more than 1 year, lenalidomide monotherapy will be maintained until disease progression"

"28d/Cycle~Induction:~ASCT：40mg qd, po/iv，D1,8,15,22，C2-4; non ASCT:20mg qd, po/iv，D1,8,15,22，C2-4;~Consolidation:~ASCT: 40mg qd, po/iv，D1,8,15,22，C5-6; non ASCT:20mg qd, po/iv，D1,8,15,22，C5-8"

"Induction:~C1, 28d/cycle Bortezomib(V）:1.3 mg/m2，H，d1、4、8、11； Lenalidomide(R)：25mg，po. qd d1-14; Dexamethasone(D)：20 mg，po/iv，D1，2, 4，5, 8，9, 11,12。"